Last reviewed · How we verify
Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways
This pilot clinical trial studies cabozantinib-s-malate in treating patients with hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Details
| Lead sponsor | Barbara Ann Karmanos Cancer Institute |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | 2013-03 |
| Completion | 2019-06-18 |
Conditions
- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer
Interventions
- cabozantinib-s-malate
- fluorine F 18 d-FMAU
- positron emission tomography
- pharmacological study
- laboratory biomarker analysis
Primary outcomes
- Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — Baseline to 4 weeks
Change in PET standard uptake value SUV levels (each value measured in g/ml). (post-treatment - pre-treatment)/pre-treatment x 100 , therefore, measured in percentage change from baseline.
Countries
United States